[{"id":"220d0ac1-a83b-4e0c-ba84-1821fcbb0575","acronym":"KRYSTAL 21","url":"https://clinicaltrials.gov/study/NCT05853575","created_at":"2023-05-10T21:04:11.391Z","updated_at":"2025-02-25T12:29:33.318Z","phase":"Phase 2","brief_title":"Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)","source_id_and_acronym":"NCT05853575 - KRYSTAL 21","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Krazati (adagrasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 02/16/2024","start_date":" 02/16/2024","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2025-02-24"},{"id":"3c07681e-1c58-4557-8010-1fc74e4cbe8d","acronym":"KRYSTAL-7","url":"https://clinicaltrials.gov/study/NCT04613596","created_at":"2021-01-19T20:33:04.646Z","updated_at":"2025-02-25T12:27:47.978Z","phase":"Phase 2/3","brief_title":"Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7","source_id_and_acronym":"NCT04613596 - KRYSTAL-7","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" PD-L1 • KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["PD-L1 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Krazati (adagrasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 806","initiation":"Initiation: 12/02/2020","start_date":" 12/02/2020","primary_txt":" Primary completion: 10/31/2028","primary_completion_date":" 10/31/2028","study_txt":" Completion: 10/31/2029","study_completion_date":" 10/31/2029","last_update_posted":"2025-02-24"},{"id":"9816427f-a3a9-4c32-ab07-2e5ae738f6f8","acronym":"KRYSTAL-2","url":"https://clinicaltrials.gov/study/NCT04330664","created_at":"2021-01-18T20:58:21.593Z","updated_at":"2025-02-25T13:40:07.291Z","phase":"Phase 1","brief_title":"Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)","source_id_and_acronym":"NCT04330664 - KRYSTAL-2","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Krazati (adagrasib) • batoprotafib (TNO155)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 04/07/2020","start_date":" 04/07/2020","primary_txt":" Primary completion: 07/29/2022","primary_completion_date":" 07/29/2022","study_txt":" Completion: 02/24/2025","study_completion_date":" 02/24/2025","last_update_posted":"2025-02-21"},{"id":"f34327ea-f002-4122-8c11-9595b9888d7d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05578092","created_at":"2022-10-13T17:58:11.601Z","updated_at":"2025-02-25T13:49:34.674Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway","source_id_and_acronym":"NCT05578092","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" EGFR • KRAS • NF1 • PTPN11","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • KRAS G12C • KRAS G12","tags":["EGFR • KRAS • NF1 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Krazati (adagrasib) • MRTX0902"],"overall_status":"Recruiting","enrollment":" Enrollment 228","initiation":"Initiation: 12/02/2022","start_date":" 12/02/2022","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 07/30/2026","study_completion_date":" 07/30/2026","last_update_posted":"2025-02-21"},{"id":"12b710b2-1109-43fb-8b55-f68f0578591b","acronym":"FIT-001","url":"https://clinicaltrials.gov/study/NCT06026410","created_at":"2023-09-07T16:09:33.674Z","updated_at":"2025-02-25T14:18:15.893Z","phase":"Phase 1","brief_title":"KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors","source_id_and_acronym":"NCT06026410 - FIT-001","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" KRAS • NRAS • HRAS","pipe":" | ","alterations":" KRAS mutation • HRAS mutation","tags":["KRAS • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Krazati (adagrasib) • darlifarnib (KO-2806)"],"overall_status":"Recruiting","enrollment":" Enrollment 270","initiation":"Initiation: 10/18/2023","start_date":" 10/18/2023","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2025-02-12"},{"id":"91232e9f-dbc4-40d6-b4a1-5da728f867c3","acronym":"KRYSTAL-16","url":"https://clinicaltrials.gov/study/NCT05178888","created_at":"2022-01-05T12:53:44.212Z","updated_at":"2025-02-25T15:27:11.129Z","phase":"Phase 1","brief_title":"Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)","source_id_and_acronym":"NCT05178888 - KRYSTAL-16","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Krazati (adagrasib)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 01/20/2022","start_date":" 01/20/2022","primary_txt":" Primary completion: 06/15/2023","primary_completion_date":" 06/15/2023","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2025-02-11"},{"id":"f1ac3a6c-0328-4766-8476-88308f4d8cc9","acronym":"KRYSTAL-10","url":"https://clinicaltrials.gov/study/NCT04793958","created_at":"2021-03-11T12:53:57.827Z","updated_at":"2025-02-25T15:34:55.257Z","phase":"Phase 3","brief_title":"Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)","source_id_and_acronym":"NCT04793958 - KRYSTAL-10","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • Krazati (adagrasib) • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 461","initiation":"Initiation: 06/24/2021","start_date":" 06/24/2021","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-11"},{"id":"75cac4e9-35d9-47ec-8b97-13bc0a811821","acronym":"","url":"https://clinicaltrials.gov/study/NCT06130254","created_at":"2023-11-14T16:14:42.662Z","updated_at":"2025-02-25T14:18:29.119Z","phase":"Phase 1","brief_title":"Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers","source_id_and_acronym":"NCT06130254","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Krazati (adagrasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 01/30/2024","start_date":" 01/30/2024","primary_txt":" Primary completion: 08/25/2030","primary_completion_date":" 08/25/2030","study_txt":" Completion: 08/25/2030","study_completion_date":" 08/25/2030","last_update_posted":"2025-02-10"},{"id":"49f30563-60f2-4168-9062-bb633cf7a950","acronym":"","url":"https://clinicaltrials.gov/study/NCT03994796","created_at":"2021-01-18T19:38:28.337Z","updated_at":"2025-02-25T14:28:26.216Z","phase":"Phase 2","brief_title":"Genetic Testing in Guiding Treatment for Patients with Brain Metastases","source_id_and_acronym":"NCT03994796","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" KRAS • BRAF • ER • PGR • ROS1 • NTRK","pipe":" | ","alterations":" HER-2 positive • EGFR mutation • HER-2 negative","tags":["KRAS • BRAF • ER • PGR • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • EGFR mutation • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rozlytrek (entrectinib) • Verzenio (abemaciclib) • Krazati (adagrasib) • paxalisib (GDC-0084)"],"overall_status":"Recruiting","enrollment":" Enrollment 186","initiation":"Initiation: 10/17/2019","start_date":" 10/17/2019","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2025-01-15"},{"id":"9c204ef9-6bfd-4558-9b99-99d53340efa6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05722327","created_at":"2023-02-10T15:00:17.094Z","updated_at":"2025-02-25T14:17:39.132Z","phase":"Phase 1","brief_title":"Phase I Trial of Adagrasib (MRTX849) in Combination with Cetuximab and Irinotecan in Patients with Colorectal Cancer","source_id_and_acronym":"NCT05722327","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS • UGT1A1","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • irinotecan • Krazati (adagrasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/06/2023","start_date":" 12/06/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2024-12-09"},{"id":"67745e72-41f8-4672-aab3-e3a773042f26","acronym":"","url":"https://clinicaltrials.gov/study/NCT06039384","created_at":"2023-09-15T18:10:07.414Z","updated_at":"2025-02-25T14:18:18.295Z","phase":"Phase 1","brief_title":"A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation","source_id_and_acronym":"NCT06039384","lead_sponsor":"Incyte Corporation","biomarkers":" EGFR • KRAS • MSI","pipe":" | ","alterations":" KRAS mutation • MSI-H/dMMR • KRAS G12C • RAS wild-type • KRAS G12","tags":["EGFR • KRAS • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • MSI-H/dMMR • KRAS G12C • RAS wild-type • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Krazati (adagrasib) • INCB99280"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 12/28/2023","start_date":" 12/28/2023","primary_txt":" Primary completion: 11/03/2025","primary_completion_date":" 11/03/2025","study_txt":" Completion: 11/03/2025","study_completion_date":" 11/03/2025","last_update_posted":"2024-11-28"},{"id":"1a77ca4f-797f-4153-b59d-eb7dbff974c0","acronym":"Neo-Kan","url":"https://clinicaltrials.gov/study/NCT05472623","created_at":"2022-07-25T20:54:32.026Z","updated_at":"2025-02-25T14:17:08.737Z","phase":"Phase 2","brief_title":"Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab","source_id_and_acronym":"NCT05472623 - Neo-Kan","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Krazati (adagrasib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 03/21/2023","start_date":" 03/21/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 02/01/2029","study_completion_date":" 02/01/2029","last_update_posted":"2024-11-25"},{"id":"30dba036-f8f6-4cfe-919b-a3ae6b2489da","acronym":"","url":"https://clinicaltrials.gov/study/NCT05375994","created_at":"2022-05-17T12:54:08.747Z","updated_at":"2025-02-25T14:16:58.488Z","phase":"Phase 1/2","brief_title":"Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients","source_id_and_acronym":"NCT05375994","lead_sponsor":"Verastem, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Krazati (adagrasib) • Avmapki (avutometinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 12/24/2024","primary_completion_date":" 12/24/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-11-12"},{"id":"96f37cc6-18ee-407c-a781-0ead0b9085d4","acronym":"ADEPPT","url":"https://clinicaltrials.gov/study/NCT05673187","created_at":"2023-01-06T16:59:13.883Z","updated_at":"2025-02-25T14:17:29.434Z","phase":"Phase 2","brief_title":"Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status","source_id_and_acronym":"NCT05673187 - ADEPPT","lead_sponsor":"ETOP IBCSG Partners Foundation","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Krazati (adagrasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 06/12/2023","start_date":" 06/12/2023","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-07-23"},{"id":"09e1bacb-5487-48d8-8aa9-3ee696982e1b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05609578","created_at":"2022-11-08T14:56:37.808Z","updated_at":"2024-07-02T16:35:01.116Z","phase":"Phase 2","brief_title":"Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation","source_id_and_acronym":"NCT05609578","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" PD-L1 • KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["PD-L1 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Krazati (adagrasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 11/28/2022","start_date":" 11/28/2022","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-24"},{"id":"60c799ec-870e-40c7-8ed6-905963014608","acronym":"","url":"https://clinicaltrials.gov/study/NCT05634525","created_at":"2022-12-02T16:57:09.231Z","updated_at":"2025-02-25T14:17:26.709Z","phase":"Phase 1","brief_title":"Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients","source_id_and_acronym":"NCT05634525","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Krazati (adagrasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 05/03/2023","start_date":" 05/03/2023","primary_txt":" Primary completion: 11/01/2027","primary_completion_date":" 11/01/2027","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2024-05-15"},{"id":"71a6ad8e-f7a3-4f71-b131-a36389cfb2ab","acronym":"KRYSTAL -19","url":"https://clinicaltrials.gov/study/NCT05840510","created_at":"2023-05-03T15:04:42.504Z","updated_at":"2024-07-02T16:35:03.747Z","phase":"Phase 1/2","brief_title":"Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)","source_id_and_acronym":"NCT05840510 - KRYSTAL -19","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Krazati (adagrasib) • Fyarro (nanoparticle albumin-bound rapamycin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 79","initiation":"Initiation: 08/07/2023","start_date":" 08/07/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-05-14"},{"id":"c5cabfd9-b1fc-42b8-8fab-a1e3bddb7d32","acronym":"KRYSTAL-1","url":"https://clinicaltrials.gov/study/NCT03785249","created_at":"2021-01-17T17:34:47.900Z","updated_at":"2024-07-02T16:35:10.063Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1","source_id_and_acronym":"NCT03785249 - KRYSTAL-1","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • Gilotrif (afatinib) • Krazati (adagrasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 822","initiation":"Initiation: 12/26/2018","start_date":" 12/26/2018","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-04-11"},{"id":"d0d6fdc2-5707-4261-9a4a-35f94b7dc483","acronym":"KRYSTAL-12","url":"https://clinicaltrials.gov/study/NCT04685135","created_at":"2021-01-19T20:47:27.375Z","updated_at":"2024-07-02T16:35:12.379Z","phase":"Phase 3","brief_title":"Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation","source_id_and_acronym":"NCT04685135 - KRYSTAL-12","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Krazati (adagrasib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 453","initiation":"Initiation: 04/01/2021","start_date":" 04/01/2021","primary_txt":" Primary completion: 12/30/2023","primary_completion_date":" 12/30/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-03-28"},{"id":"c64c91af-a6fb-413f-80e9-a4ace1009456","acronym":"","url":"https://clinicaltrials.gov/study/NCT05848843","created_at":"2023-05-08T15:04:04.546Z","updated_at":"2025-02-25T14:17:54.699Z","phase":"Phase 1","brief_title":"A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations","source_id_and_acronym":"NCT05848843","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Krazati (adagrasib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/25/2023","start_date":" 04/25/2023","primary_txt":" Primary completion: 01/16/2024","primary_completion_date":" 01/16/2024","study_txt":" Completion: 01/16/2024","study_completion_date":" 01/16/2024","last_update_posted":"2024-01-23"},{"id":"ff3997d8-95da-4693-9426-fc83b35fcd36","acronym":"","url":"https://clinicaltrials.gov/study/NCT05162443","created_at":"2021-12-17T17:31:20.204Z","updated_at":"2024-07-02T16:35:47.614Z","phase":"","brief_title":"Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation","source_id_and_acronym":"NCT05162443","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Krazati (adagrasib)"],"overall_status":"Approved for marketing","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2023-05-19"},{"id":"bcae8213-605b-4728-8da1-32f213b27bb0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05263986","created_at":"2022-03-03T14:06:11.210Z","updated_at":"2025-02-25T14:16:44.730Z","phase":"Phase 1","brief_title":"The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05263986","lead_sponsor":"Zai Lab (Shanghai) Co., Ltd.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Krazati (adagrasib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 05/30/2022","start_date":" 05/30/2022","primary_txt":" Primary completion: 10/31/2023","primary_completion_date":" 10/31/2023","study_txt":" Completion: 10/31/2023","study_completion_date":" 10/31/2023","last_update_posted":"2023-02-27"},{"id":"4bf93b69-0cce-4692-8a52-e1d41b54ad12","acronym":"KRYSTAL 14","url":"https://clinicaltrials.gov/study/NCT04975256","created_at":"2021-07-23T13:52:35.255Z","updated_at":"2024-07-02T16:35:59.402Z","phase":"Phase 1","brief_title":"Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)","source_id_and_acronym":"NCT04975256 - KRYSTAL 14","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Krazati (adagrasib) • BI 1701963"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 08/12/2021","start_date":" 08/12/2021","primary_txt":" Primary completion: 11/02/2022","primary_completion_date":" 11/02/2022","study_txt":" Completion: 11/15/2022","study_completion_date":" 11/15/2022","last_update_posted":"2022-12-08"}]